These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9426419)

  • 1. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.
    Musholt TJ; Musholt PB; Dehdashti F; Moley JF
    Surgery; 1997 Dec; 122(6):1049-60; discussion 1060-1. PubMed ID: 9426419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
    Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
    Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
    van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
    J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.
    Yamada A; Oguchi K; Fukushima M; Imai Y; Kadoya M
    Ann Nucl Med; 2006 Nov; 20(9):597-604. PubMed ID: 17294670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
    de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
    Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.
    Jang HW; Choi JY; Lee JI; Kim HK; Shin HW; Shin JH; Kim SW; Chung JH
    Endocr J; 2010; 57(12):1045-54. PubMed ID: 20978365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
    Khan N; Oriuchi N; Higuchi T; Endo K
    Cancer Control; 2005 Oct; 12(4):254-60. PubMed ID: 16258498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
    Shulkin BL; Thompson NW; Shapiro B; Francis IR; Sisson JC
    Radiology; 1999 Jul; 212(1):35-41. PubMed ID: 10405717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.
    Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Kasperbauer JL; Reading CC; Björo T; Hay ID; Lowe VJ
    Mol Imaging Biol; 2010 Oct; 12(5):547-53. PubMed ID: 19949985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature.
    Gotthardt M; Battmann A; Höffken H; Schurrat T; Pollum H; Beuter D; Gratz S; Béhé M; Bauhofer A; Klose KJ; Behr TM
    Nucl Med Commun; 2004 May; 25(5):439-43. PubMed ID: 15100501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.
    Barollo S; Bertazza L; Watutantrige-Fernando S; Censi S; Cavedon E; Galuppini F; Pennelli G; Fassina A; Citton M; Rubin B; Pezzani R; Benna C; Opocher G; Iacobone M; Mian C
    PLoS One; 2016; 11(5):e0156044. PubMed ID: 27224648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.